We found that mechanistically, TVA antagonizes cell‐surface protein‐coupled receptor GPR43 and activates the cAMP‐PKA‐CREB axis, leading to enhanced effector CD8+ T cell function and anti‐tumor immunity. Here, CD8A is linked to neoplasm.